Free Trial
→ Banks aren’t ready for this altcoin—are you? (From Crypto 101 Media) (Ad)
OTCMKTS:CYDY

CytoDyn Q4 2023 Earnings Report

CytoDyn logo
$0.35 0.00 (-0.59%)
As of 06/13/2025 03:59 PM Eastern
ProfileEarnings History

CytoDyn EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CytoDyn Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CytoDyn Announcement Details

Quarter
Q4 2023
Date
9/13/2023
Time
N/A
Conference Call Date
Thursday, September 14, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

CytoDyn's Q4 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Friday, August 8, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

CytoDyn's Q4 2023 Press ReleasePress Release
(8-K)

CytoDyn Earnings Headlines

CytoDyn Announces New Data Suggesting Novel Mechanism Of Action Of Leronlimab In Solid Tumors
May 15, 2025 | nasdaq.com
CytoDyn Releases ESMO Breast Cancer Meeting Poster
May 15, 2025 | globenewswire.com
Banks aren’t ready for this altcoin—are you?
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.
June 15, 2025 | Crypto 101 Media (Ad)
CytoDyn's new data shows leronlimab could treat solid tumors
May 13, 2025 | msn.com
CytoDyn highlights potential of lead drug against solid tumors with new data
May 13, 2025 | seekingalpha.com
CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
May 13, 2025 | globenewswire.com
See More CytoDyn Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CytoDyn? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CytoDyn and other key companies, straight to your email.

About CytoDyn

CytoDyn (OTCMKTS:CYDY), a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

View CytoDyn Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles